Active Ingredient History
Ecraprost [AS 013, Circulase] is a prodrug of prostaglandin E(1) within lipid microspheres that is being developed in Japan by Mitsubishi Pharma Corporation and Asahi Glass. It was originally in development with Welfide Corporation. On 1 October 2001, Welfide Corporation (formerly Yoshitomi) merged with Mitsubishi-Tokyo Pharmaceuticals to form Mitsubishi Pharma Corporation. The new company is a subsidiary of Mitsubishi Chemical. Taisho and Seikagaku Corporation had been involved in the development of ecraprost but discontinued their licences to do so. The effects of ecraprost on reperfusion injury, in preclinical studies, had been reported by Taisho. Ecraprost is in phase II in Japan and was in phase II in Europe for the treatment of peripheral arterial disease. It was also in a phase II study in the treatment of diabetic neuropathies. However, this is no longer an active indication. A phase III trial using a lipid emulsion of ecraprost [Circulase] is underway with Mitsubishi Pharma Corporation in the US, using ecraprost for the treatment of patients with severe peripheral arterial disease, which, because of decreased blood flow to the extremities, can lead to painful ulcers on the legs and feet and subsequent amputation. Alpha Therapeutic Corporation (a former subsidiary of Mitsubishi Pharma) was initially involved in trials of ecraprost in the US, but this responsibility has been taken over by the parent company. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Kidney Injury (Phase 4)
Alprostadil (Phase 4)
Arterial Occlusive Diseases (Phase 4)
Arteriosclerosis Obliterans (Phase 2)
Breast Neoplasms (Phase 1)
Child (Phase 2/Phase 3)
Chronic Limb-Threatening Ischemia (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetic Nephropathies (Phase 4)
Extracorporeal Membrane Oxygenation (Phase 2)
Heart Defects, Congenital (Phase 1)
Heart Failure (Phase 3)
HIV Infections (Phase 2)
Hypertension, Pulmonary (Phase 2)
Infant, Newborn (Phase 2)
Infant, Premature, Diseases (Phase 2)
Infertility (Phase 2)
Intermittent Claudication (Phase 3)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Labor, Induced (Phase 4)
Labor Pain (Phase 3)
Liver Transplantation (Phase 2)
Macular Degeneration (Phase 3)
Melanoma (Phase 1)
Microsurgery (Phase 4)
Optic Neuropathy, Ischemic (Phase 2)
Pediatrics (Phase 4)
Percutaneous Coronary Intervention (Phase 3)
Peripheral Arterial Disease (Phase 2)
Peripheral Vascular Diseases (Phase 3)
Pregnancy (Phase 4)
Prostatic Neoplasms (Phase 2)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Respiratory Distress Syndrome (Phase 2)
Respiratory Distress Syndrome, Newborn (Phase 2)
Respiratory Insufficiency (Phase 2)
Sclerosis (Phase 2)
Sexual Dysfunction, Physiological (Phase 2)
Sexual Health (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Streptococcal Infections (Phase 2)
Stroke (Phase 4)
Thrombosis (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue